Education
About Us
Working with TipRanks
Follow Us
Madrigal Pharmaceuticals Inc (MDGL)
NASDAQ:MDGL
MDGL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$200.63 - $377.46
Previous CloseN/A
Volume47.78K
Average Volume (3M)375.68K
Market Cap
$7.71B
Enterprise Value$6.04B
Total Cash (Recent Filing)$797.02M
Total Debt (Recent Filing)$1.05M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Oct 30, 2025EPS Estimate
-2.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding22,289,015
10 Day Avg. Volume452,625
30 Day Avg. Volume375,684
Financial Highlights & Ratios
PEG Ratio-1.47
Price to Book (P/B)8.70
Price to Sales (P/S)36.44
P/FCF Ratio-14.36
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue11.72
Enterprise Value/Gross Profit12.16
Enterprise Value/Ebitda-21.95
Forecast
1Y Price Target
$447.90Price Target Upside28.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
EarningsMDGL reported $212.8mn in net revenue for Rezdiffra, significantly beating above-consensus estimates, demonstrating strong commercial execution.
Intellectual PropertyA new use patent for Rezdiffra's weight-based dosing should provide intellectual property protection through 2045.
Market ExpansionMDGL is preparing for potential European approval for Rezdiffra and subsequent launch in Germany, where management believes tailwinds from the U.S. launch & MASH treatment guidelines in EU should facilitate strong uptake.
Bears Say
Competitive PressureThere are increasing downside risks due to the impending launch of the GLP-1s and other competitive factors.
Financial PerformanceMDGL reported a net loss of $42.2M due to increased R&D and SG&A expenses related to Rezdiffra commercial preparation and launch.
Market SkepticismConcerns exist over the opportunity size, with Rezdiffra's recent performance looking priced in at this point.
Madrigal Pharmaceuticals News
MDGL FAQ
What was Madrigal Pharmaceuticals Inc’s price range in the past 12 months?
Madrigal Pharmaceuticals Inc lowest stock price was $200.63 and its highest was $377.46 in the past 12 months.
What is Madrigal Pharmaceuticals Inc’s market cap?
Madrigal Pharmaceuticals Inc’s market cap is $7.71B.
When is Madrigal Pharmaceuticals Inc’s upcoming earnings report date?
Madrigal Pharmaceuticals Inc’s upcoming earnings report date is Oct 30, 2025 which is in 79 days.
How were Madrigal Pharmaceuticals Inc’s earnings last quarter?
Madrigal Pharmaceuticals Inc released its earnings results on Aug 05, 2025. The company reported -$1.9 earnings per share for the quarter, beating the consensus estimate of -$3.554 by $1.654.
Is Madrigal Pharmaceuticals Inc overvalued?
According to Wall Street analysts Madrigal Pharmaceuticals Inc’s price is currently Undervalued.
Does Madrigal Pharmaceuticals Inc pay dividends?
Madrigal Pharmaceuticals Inc does not currently pay dividends.
What is Madrigal Pharmaceuticals Inc’s EPS estimate?
Madrigal Pharmaceuticals Inc’s EPS estimate is -2.06.
How many shares outstanding does Madrigal Pharmaceuticals Inc have?
Madrigal Pharmaceuticals Inc has 22,289,015 shares outstanding.
What happened to Madrigal Pharmaceuticals Inc’s price movement after its last earnings report?
Madrigal Pharmaceuticals Inc reported an EPS of -$1.9 in its last earnings report, beating expectations of -$3.554. Following the earnings report the stock price went up 8.587%.
Which hedge fund is a major shareholder of Madrigal Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in MDGL
Madrigal Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$447.90 (28.15% Upside)
$447.90 (28.15% Upside)
Blogger Sentiment
Bullish
MDGL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 108.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.90%
12-Months-Change
Fundamentals
Return on Equity
-36.30%
Trailing 12-Months
Asset Growth
-7.67%
Trailing 12-Months
Company Description
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
MDGL Company Deck
MDGL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Madrigal Pharmaceuticals reported a strong quarter with significant revenue growth, strategic patent extensions, and promising international and pipeline expansions. However, concerns regarding increased expenses and potential market competition somewhat temper the outlook.View all MDGL earnings summariesMDGL Stock 12 Month Forecast
Average Price Target
$447.90
▲(28.15% Upside)
Technical Analysis
Corcept Therapeutics
―
Halozyme
―
BridgeBio Pharma
―
Revolution Medicines
―
Roivant Sciences
―
Ownership Overview
19.50% Insiders
25.31% Mutual Funds
<0.01% Other Institutional Investors
41.76% Public Companies and
Individual Investors